1. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]
- Author
-
A, Dembińska-Kieć, E, Kostka-Trabka, L, Grodzińska, K, Bieroń, A, Kedzior, M, Basista, A, Zmuda, E, Trabka, M, Slawiński, and H, Czarnecka
- Subjects
Adult ,Hypertriglyceridemia ,Male ,Clofibric Acid ,Cholesterol, HDL ,Hypercholesterolemia ,Humans ,Female ,Arteriosclerosis Obliterans ,Clofibrate ,Triglycerides ,Hypolipidemic Agents - Abstract
In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III). The study parameters were evaluated prior to and after the four weeks of treatment. Administration of etofibrate resulted in a significant decrease in serum cholesterol and triglyceride levels, the decrease in LDL-/HDL-cholesterol-ratio due mainly to an elevation of the HDL-cholesterol fraction, an increase in plasma fibrinolytic activity, an increased peripheral blood flow in the ischemic leg, and an increase in the pain-free walking distance. Thus, etofibrate applied twice daily might be recommended for the treatment of hyperlipidemic patients with signs of arteriosclerosis obliterans, Fontaine stage II/III.
- Published
- 1989